SG11201507332SA - Therapeutic compounds and compositions - Google Patents

Therapeutic compounds and compositions

Info

Publication number
SG11201507332SA
SG11201507332SA SG11201507332SA SG11201507332SA SG11201507332SA SG 11201507332S A SG11201507332S A SG 11201507332SA SG 11201507332S A SG11201507332S A SG 11201507332SA SG 11201507332S A SG11201507332S A SG 11201507332SA SG 11201507332S A SG11201507332S A SG 11201507332SA
Authority
SG
Singapore
Prior art keywords
compositions
therapeutic compounds
therapeutic
compounds
Prior art date
Application number
SG11201507332SA
Other languages
English (en)
Inventor
Giovanni Cianchetta
Janeta Popovici-Muller
Robert Zahler
Sheldon Cao
Xiaolei Wang
Zhixiong Ye
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51535825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201507332S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of SG11201507332SA publication Critical patent/SG11201507332SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG11201507332SA 2013-03-15 2014-03-13 Therapeutic compounds and compositions SG11201507332SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2013/072688 WO2014139144A1 (en) 2013-03-15 2013-03-15 Therapeutic compounds and compositions
PCT/CN2014/000260 WO2014139325A1 (en) 2013-03-15 2014-03-13 Therapeutic compounds and compositions

Publications (1)

Publication Number Publication Date
SG11201507332SA true SG11201507332SA (en) 2015-10-29

Family

ID=51535825

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201507332SA SG11201507332SA (en) 2013-03-15 2014-03-13 Therapeutic compounds and compositions

Country Status (22)

Country Link
US (3) US20160046579A1 (pt)
EP (1) EP2970189B1 (pt)
JP (2) JP6374413B2 (pt)
CN (1) CN105121425A (pt)
AR (1) AR095557A1 (pt)
AU (1) AU2014231564B2 (pt)
BR (1) BR112015023760A2 (pt)
CA (1) CA2903067A1 (pt)
CL (1) CL2015002767A1 (pt)
CR (1) CR20150571A (pt)
ES (1) ES2803548T3 (pt)
HK (1) HK1216175A1 (pt)
IL (1) IL241352A0 (pt)
MX (1) MX2015012882A (pt)
NI (1) NI201500140A (pt)
PE (1) PE20151793A1 (pt)
PH (1) PH12015502161A1 (pt)
RU (1) RU2015143908A (pt)
SG (1) SG11201507332SA (pt)
TW (1) TW201444797A (pt)
WO (2) WO2014139144A1 (pt)
ZA (1) ZA201506487B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014139144A1 (en) * 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
PL3193611T3 (pl) 2014-09-17 2021-10-04 Celgene Car Llc Inhibitory mk2 i ich zastosowania
CN104817490B (zh) * 2015-05-13 2017-10-13 北京大学 氨基二硫代甲酸酯类化合物及其制备方法与应用
EP3386591B1 (en) 2015-12-09 2020-06-24 Cadent Therapeutics, Inc. Heteroaromatic nmda receptor modulators and uses thereof
EP4219507A3 (en) 2015-12-09 2023-08-16 Novartis AG Thienopyrimidinone nmda receptor modulators and uses thereof
GB201617758D0 (en) 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
US11274107B2 (en) 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
NZ763766A (en) 2017-03-20 2023-07-28 Novo Nordisk Healthcare Ag Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
CN107298685A (zh) * 2017-06-29 2017-10-27 上海合全药业股份有限公司 一种8‑(叔丁氧羰基)‑1‑氧杂‑8‑氮杂螺[4.5]癸烷‑2‑羧酸的合成方法
WO2019035865A1 (en) 2017-08-15 2019-02-21 Agios Pharmaceuticals Inc. MODULATORS OF PYRUVATE KINASE AND THEIR USE
PL3700902T3 (pl) 2017-10-27 2023-09-04 Boehringer Ingelheim International Gmbh Inhibitory trpc6
EP3604288B1 (en) 2018-08-02 2024-04-10 Development Center for Biotechnology Regioselective one-step process for synthesizing 2-hydroxyquinoxaline
EA202190431A1 (ru) 2018-08-03 2021-06-11 Кэйдент Терапьютикс, Инк. Гетероароматические модуляторы nmda рецептора и их применение
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
WO2020129877A1 (ja) * 2018-12-18 2020-06-25 株式会社デ・ウエスタン・セラピテクス研究所 イソキノリンスルホニルクロリド酸付加塩及びその製造方法
WO2021029450A1 (ko) * 2019-08-09 2021-02-18 한국화학연구원 신규한 피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물
WO2022034146A1 (en) 2020-08-13 2022-02-17 Boehringer Ingelheim International Gmbh Treatment of cognitive impairement associated with schizophrenia
CN112773800B (zh) * 2021-01-25 2021-10-15 南通大学 哌啶-1-二硫代甲酸-3-甲基-1，4-二氧-1，4-二氢萘-2-甲基酯的用途
WO2022170200A1 (en) 2021-02-08 2022-08-11 Global Blood Therapeutics, Inc. 1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease
WO2023116774A1 (zh) 2021-12-21 2023-06-29 赛诺哈勃药业（成都）有限公司 含二氮杂亚基磺酰结构的化合物及其在医药上的用途
CN115073422A (zh) * 2022-07-28 2022-09-20 成都普瑞熙药业有限公司 一种制备4-(1-甲基-1h-吡唑-5-基)哌啶及其盐的方法
ES2975743A1 (es) * 2022-11-22 2024-07-12 Moehs Iberica Sl Metodo de preparacion de mitapivat, intermedios de sintesis de mitapivat y metodos de preparacion de los mismos

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE907739C (de) 1949-07-23 1954-02-18 Kalle & Co Ag Verfahren zur Herstellung von Kopien, besonders Druckformen, mit Hilfe von Diazoverbindungen und dafuer verwendbares lichtempfindliches Material
GB935538A (en) 1959-04-06 1963-08-28 Stop Motion Devices Corp Stop-motion head for use on knitting machines
US4474599A (en) 1982-07-14 1984-10-02 The Dow Chemical Company 1-(Pyridyl)-1H-1,2,3-triazole derivatives, and use as herbicidal agents
GB8325370D0 (en) 1983-09-22 1983-10-26 Fujisawa Pharmaceutical Co Benzoxazoline and benzothiazoline derivatives
JPS61129129A (ja) 1984-11-28 1986-06-17 Kureha Chem Ind Co Ltd 抗腫瘍剤
FI855180A (fi) 1985-01-18 1986-07-19 Nissan Chemical Ind Ltd Pyrazolsulfonamidderivat, foerfarande foer dess framstaellande och det innehaollande ograesgift.
EP0246749A3 (en) 1986-05-17 1988-08-31 AgrEvo UK Limited Triazole herbicides
JPS6339875A (ja) 1986-08-05 1988-02-20 Nissin Food Prod Co Ltd ピリミジン誘導体
US4775762A (en) 1987-05-11 1988-10-04 The Dow Chemical Company Novel (1H-1,2,3-triazol-1-yl)pyridines
DE3813885A1 (de) 1988-04-20 1989-11-02 Schering Ag 1-chlorpyrimidinyl-1h-1,2,4-triazol-3-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, fungizider und pflanzenwachstumsregulierender wirkung
DE3813886A1 (de) 1988-04-20 1989-11-02 Schering Ag 1-triazinyl-1h-1,2,4-triazol-3- sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, fungizider und pflanzenwachstumsregulierender wirkung
US5220028A (en) 1988-10-27 1993-06-15 Nissan Chemical Industries, Ltd. Halogeno-4-methylpyrazoles
MY106533A (en) 1990-02-20 1995-06-30 Sumitomo Chemical Co A 4-tert.-butyl imidazole derivative and its production and use.
CA2036147A1 (en) 1990-06-29 1991-12-30 Hiroki Tomioka A 1-pyridylimidazole derivative and its production and use
CZ129493A3 (en) 1990-12-31 1994-03-16 Monsanto Co Elimination of pesticides influence on plants
US5252590A (en) 1991-06-28 1993-10-12 Sumitomo Chemical Company, Limited 1-pyridylimidazole derivative
JPH0625177A (ja) 1992-07-09 1994-02-01 Nissan Chem Ind Ltd ピラゾール誘導体及び除草剤
JP3719612B2 (ja) 1993-06-14 2005-11-24 塩野義製薬株式会社 ヘテロ環を含有する尿素誘導体
DE19541146A1 (de) 1995-10-25 1997-04-30 Schering Ag Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
US6172005B1 (en) 1997-03-11 2001-01-09 E. I. Du Pont De Nemours And Company Heteroaryl azole herbicides
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
DE19743435A1 (de) 1997-10-01 1999-04-08 Merck Patent Gmbh Benzamidinderivate
US6214879B1 (en) 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
AU754204B2 (en) 1998-09-01 2002-11-07 Bristol-Myers Squibb Company Potassium channel inhibitors and method
PL347138A1 (en) 1998-09-18 2002-03-25 Basf Ag 4-aminopyrrolopyrimidines as kinase inhibitors
US6492408B1 (en) 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
DK1214296T3 (da) 1999-09-04 2004-07-05 Astrazeneca Ab Substituerede N-phenyl-2-hydroxy-2-methyl-3,3,3-trifluorpropanamidderivater, der forhöjer pyruvatdehydrogenaseaktivitet
JP2002193710A (ja) 2000-12-25 2002-07-10 Kumiai Chem Ind Co Ltd ピリミジン又はトリアジン誘導体及び農園芸用殺菌剤
US20040198979A1 (en) 2001-05-07 2004-10-07 Dashyant Dhanak Sulfonamides
KR100866463B1 (ko) 2001-08-15 2008-10-31 이 아이 듀폰 디 네모아 앤드 캄파니 무척추 해충 방제용 오르토-치환 아릴 아미드
JP2003081937A (ja) 2001-09-07 2003-03-19 Bayer Ag ベンゼンスルホンアミド誘導体
AU2002361577A1 (en) 2001-10-30 2003-05-12 Merck And Co., Inc. Tyrosine kinase inhibitors
US7148236B2 (en) 2002-01-17 2006-12-12 Merck & Co., Inc. Modulators of acetylcholine receptors
CN100445276C (zh) 2002-03-13 2008-12-24 詹森药业有限公司 用作组蛋白去乙酰酶抑制剂的磺酰基衍生物
AU2003234464B2 (en) 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
GB0215775D0 (en) 2002-07-06 2002-08-14 Astex Technology Ltd Pharmaceutical compounds
DE60334386D1 (de) 2002-08-09 2010-11-11 Merck Sharp & Dohme Tyrosinkinaseinhibitoren
EP1556040A1 (en) 2002-10-24 2005-07-27 Sterix Limited Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2
MXPA05006354A (es) * 2002-12-13 2005-08-26 Smithkline Beecham Corp Antagonistas ccr5 como agentes terapeuticos.
JP4629657B2 (ja) * 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物
EP1635800A2 (en) 2003-06-10 2006-03-22 Kalypsys, Inc. Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
US6818631B1 (en) 2003-08-15 2004-11-16 Nippon Soda Co. Ltd. Fungicidal pyrimidine derivatives
US20080051414A1 (en) 2003-10-14 2008-02-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
WO2006033628A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2006038594A1 (ja) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
WO2006043950A1 (en) 2004-10-20 2006-04-27 Smithkline Beecham Corporation Il-8 receptor antagonists
US20080004269A1 (en) 2004-11-04 2008-01-03 Yuelian Xu Pyrazolylmethy Heteroaryl Derivatives
SE0402762D0 (sv) 2004-11-11 2004-11-11 Astrazeneca Ab Indazole sulphonamide derivatives
US8076370B2 (en) 2005-05-03 2011-12-13 Ranbaxy Laboratories Limited Antimicrobial agents
US20100105657A1 (en) 2005-07-05 2010-04-29 Astrazeneca Ab Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease
WO2007008143A1 (en) 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
WO2007016354A1 (en) 2005-07-29 2007-02-08 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
DK1910384T3 (da) 2005-08-04 2012-12-17 Sirtris Pharmaceuticals Inc Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser
JP2007238458A (ja) 2006-03-06 2007-09-20 D Western Therapeutics Institute Inc 新規なイソキノリン誘導体及びこれを含有する医薬
EP1999121A1 (en) 2006-03-17 2008-12-10 AstraZeneca AB Novel tetralins as 5-ht6 modulators
EP2004619A1 (en) 2006-03-23 2008-12-24 Amgen Inc. 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases
EP2001480A4 (en) 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
ES2614931T3 (es) 2006-08-04 2017-06-02 Beth Israel Deaconess Medical Center Inhibidores de la piruvato cinasa y métodos de tratamiento de enfermedad
US20090247499A1 (en) 2006-08-21 2009-10-01 Fletcher Joan M Sulfonylated piperazines as cannabinoid-1 receptor modulators
ATE550334T1 (de) 2006-09-01 2012-04-15 Otsuka Agritechno Co Ltd N-pyridylpiperidinverbindung, verfahren zu ihrer herstellung und schädlingsbekämpfungsmittel
ES2559521T3 (es) 2006-10-16 2016-02-12 Thesan Pharmaceuticals, Inc. Pirazolil tienopiridinas terapéuticas
HUP0600810A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
DE602008000809D1 (de) * 2007-03-23 2010-04-29 Icagen Inc Ionenkanal-Hemmer
CA2693159C (en) 2007-07-18 2016-05-24 Shawn T. Branum Sulfonamides as trpm8 modulators
EP2053045A1 (en) 2007-10-26 2009-04-29 Syngenta Participations AG Novel imidazole derivatives
CN101835773A (zh) 2007-10-26 2010-09-15 先正达参股股份有限公司 新颖的咪唑衍生物
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
MX2011001426A (es) * 2008-08-05 2011-03-21 Targegen Inc Metodos para tratar la talasemia.
EP2331518A1 (en) * 2008-08-22 2011-06-15 Evotec AG New bradykinin b1 antagonists
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
EP2344453B1 (en) 2008-10-09 2016-12-28 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
AU2010234526B2 (en) 2009-04-06 2016-07-21 Agios Pharmaceuticals, Inc. Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use
TW201105655A (en) 2009-04-22 2011-02-16 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
CA2760929C (en) 2009-05-04 2018-01-02 Agios Pharmaceuticals, Inc. Pkm2 activators for use in the treatment of cancer
WO2010130638A1 (en) * 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
TWI598337B (zh) * 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
AU2011210567B2 (en) 2010-01-29 2015-04-16 Dana-Farber Cancer Institute, Inc. Small molecules for the modulation of MCL-1 and methods of modulatiing cell death, cell division, cell differentiation and methods of treating disorders
CN103819393A (zh) 2010-03-01 2014-05-28 瑞科西有限公司 化合物及其治疗应用
US20130109672A1 (en) 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
DE102010048800A1 (de) 2010-10-20 2012-05-10 Merck Patent Gmbh Chinoxalinderivate
FR2967674B1 (fr) 2010-11-23 2012-12-14 Pf Medicament Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
CA2821975A1 (en) * 2010-12-17 2012-06-21 Shunqi Yan N-(4-(azetidine-1-carbonyl)phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase m2 pkm2 modulators
EP2704720B1 (en) * 2011-05-03 2019-08-07 Agios Pharmaceuticals, Inc. Pyruvate kinase r activators for use in therapy
CN102805860A (zh) * 2011-05-30 2012-12-05 复旦大学 丙酮酸激酶2乙酰化抑制剂及其用途
WO2014139144A1 (en) * 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions

Also Published As

Publication number Publication date
US20150336931A1 (en) 2015-11-26
US9108921B2 (en) 2015-08-18
IL241352A0 (en) 2015-11-30
EP2970189B1 (en) 2020-05-06
CR20150571A (es) 2016-01-06
US20160046579A1 (en) 2016-02-18
WO2014139325A1 (en) 2014-09-18
TW201444797A (zh) 2014-12-01
EP2970189A1 (en) 2016-01-20
CL2015002767A1 (es) 2016-12-30
PE20151793A1 (es) 2015-12-10
AU2014231564A2 (en) 2015-10-22
US9365545B2 (en) 2016-06-14
CA2903067A1 (en) 2014-09-18
HK1216175A1 (zh) 2016-10-21
AU2014231564A1 (en) 2015-09-10
WO2014139144A1 (en) 2014-09-18
US20140288081A1 (en) 2014-09-25
AU2014231564B2 (en) 2018-07-12
AR095557A1 (es) 2015-10-28
JP6374413B2 (ja) 2018-08-15
PH12015502161A1 (en) 2016-01-25
ES2803548T3 (es) 2021-01-27
JP2016512203A (ja) 2016-04-25
BR112015023760A2 (pt) 2017-07-18
EP2970189A4 (en) 2016-08-10
MX2015012882A (es) 2015-12-03
ZA201506487B (en) 2016-11-30
CN105121425A (zh) 2015-12-02
RU2015143908A (ru) 2017-04-21
NI201500140A (es) 2015-11-24
JP2017105832A (ja) 2017-06-15

Similar Documents

Publication Publication Date Title
HK1216175A1 (zh) 治療性化合物和組合物
HK1226301A1 (zh) 修飾的治療劑及其組合物
HK1254296A1 (zh) 治療性化合物和其用途
IL286759A (en) Therapeutic methods and preparations
HK1213798A1 (zh) 治療性化合物和組合物
GB201320729D0 (en) Therapeutic compounds and their use
SI3030262T1 (sl) Kombiniran farmacevtski sestavek
HK1220920A1 (zh) 治療性組合物和其用途
GB201301895D0 (en) Pharmaceutical compositions
HK1217092A1 (zh) 治療性化合物及其用途
GB201308440D0 (en) Therapeutic
SG11201601477VA (en) Pharmaceutical composition
GB2516838B (en) Fungicidal compositions and their use
GB201311361D0 (en) Compounds and their therapeutic use
GB201318668D0 (en) Sonosensitive therapeutic
GB201308736D0 (en) Compounds and their therapeutic use
EP3065746A4 (en) Therapeutic compositions
PT2948129T (pt) Compostos terapêuticos
HK1220143A1 (zh) 藥物組合物
AP2015008890A0 (en) Pharmaceutical compositions
GB201314286D0 (en) Therapeutic Compounds
GB201312499D0 (en) Therapeutic compounds
GB201320905D0 (en) Therapeutic compounds
GB201319255D0 (en) Therapeutic compositions and methods
GB201317804D0 (en) Therapeutic compounds and their use